Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 14 h ago

Invivyd, Inc.: MAVERICK CAPITAL LTD amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Maverick Capital Ltd filed an amended Schedule 13G with the SEC disclosing a change to its stake in Invivyd, Inc. under accession number 0001012975-26-001059. The filing updates the hedge fund's previously reported beneficial ownership position in the clinical-stage biotech, which develops antibody therapies for viral infectious diseases. Schedule 13G amendments are typically triggered when a passive investor's ownership crosses the 5% threshold or moves by more than 5% of the class, though the headline did not specify the exact revised percentage. Investors will watch for the full filing details to gauge whether Maverick increased or trimmed its position, a signal of institutional conviction in Invivyd's pipeline.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Invivyd, Inc., Maverick Capital Ltd